Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Potsdam – page 53

1 819 clinical trials in Potsdam, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Potsdam at a glance
1 819
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 819 trials in Potsdam

Open in trial search

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Caffeine
  • Sponsor:UCB Biopharma

Study on the Effectiveness and Safety of Lifileucel and Pembrolizumab for Patients with Untreated, Unresectable, or Metastatic Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Study on Venetoclax and Drug Combination for Adults with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Lymphangioma

Recruiting

Study on Alpelisib for Treating Lymphatic Malformations in Patients with PIK3CA Mutation

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study of Nipocalimab in Pregnant Women at Risk of Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on Hilar Cholangiocarcinoma Treatment Using Porfimer Sodium and Foscan for Patients with Bile Duct Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Universitaet Leipzig

Study on Rituximab for Patients with Acute Myocardial Infarction

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut Für Frauengesundheit GmbH

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Potsdam

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for triple-negative, HER2-positive, and hormone receptor-positive variants. Research encompasses new combination therapies and targeted treatments.

  • Early-stage breast cancer interventions
  • HPV-positive oropharyngeal cancer treatments
  • Advanced treatment strategies

Multiple studies are evaluating novel drug combinations and personalized therapeutic approaches.

02 Dermatological Studies

Clinical research targeting various skin conditions, including atopic dermatitis and chronic skin disorders. Studies focus on both topical and systemic treatments.

  • Actinic keratosis treatments
  • Hidradenitis suppurativa therapy
  • Plaque psoriasis management

Investigations include both traditional and innovative therapeutic approaches for skin conditions.

03 Neurological Research

Studies focusing on multiple sclerosis treatment options, evaluating new medications and comparing their effectiveness to existing therapies.

  • Relapsing-remitting MS treatments
  • Novel therapeutic approaches
  • Disease modification strategies

Research aims to improve treatment outcomes and quality of life for patients with neurological conditions.

04 Cardiovascular Studies

Research focusing on cardiovascular disease management and innovative treatments for related conditions, including studies on lipid management.

  • Lipoprotein management
  • Cholesterol reduction therapies
  • Cardiovascular risk prevention

Trials aim to reduce major cardiovascular events and improve patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.